Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915038 · ClinicalTrials.gov registry record · NA
ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
A NA study of Throat Cancer and HPV Positive Cancer, sponsored by Indiana University.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT06915038 is a NA study of Throat Cancer and HPV Positive Cancer that is actively recruiting participants, run by Indiana University. The registered enrollment target is 120 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06915038, a NA study of Throat Cancer and HPV Positive Cancer, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck dissection.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST NavDx
- RADIATION Adjuvant Radiation 30 Gray
- RADIATION Adjuvant Radiation 40 Gray
Study Locations (2)
Indiana
- IU Health Joe and Shelly Schwarz Cancer Center - Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-06-11 |
| Est. Completion | 2028-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06915038
The ClinicalTrials.gov registry entry for NCT06915038 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Throat Cancer appearing as the primary indexed condition, and to 3 interventions - of which NavDx is the first listed.
NCT06915038 reports 2 study locations spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT06915038 about?
NCT06915038 is a clinical study titled "ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx". This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck dissection.
What is the current status of trial NCT06915038?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-06-11. Estimated completion is 2028-12.
What conditions does trial NCT06915038 study?
This clinical trial studies the following conditions: Throat Cancer, HPV Positive Cancer, Tonsil Cancer, Squamous Cell Carcinoma of Oropharynx.
What interventions are being tested in trial NCT06915038?
The interventions under investigation include: NavDx (DIAGNOSTIC_TEST), Adjuvant Radiation 30 Gray (RADIATION), Adjuvant Radiation 40 Gray (RADIATION).
Who is sponsoring clinical trial NCT06915038?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915038 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Throat Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.